DocWire News Editors

DocwireNews

Hemophilia is a costly and complex disease, and while there has been “incredible growth” in treatment options—48 products are currently on the market—the increased product choice is not driving down costs, said Sam Leo, PharmD, director of specialty clinical programs at Magellan Rx Management in New York.
Dr. Leo and Gary Tereso, PharmD, a senior clinical pharmacist at Health New England in Massachusetts, discussed the roles of various stakeholders in hemophilia care, as well as spending considerations from a payer perspective at the Specialty Connect event yesterday.
The average cost of care for a patient with hemophilia is $300,000 per-member, per-year, with factor replacement products representing up to 94% of total costs for patients with severe disease. The rarity and genetic nature of hemophilia, as well as the wide range in cost per patient, can lead to substantial variation in the number of patients and total hemophilia-related costs for health plans.
More and more agents in the pipeline are highly complex, including more extended half-life agents and non-replacement therapies, as well as gene therapy. There are a lot of unanswered questions with these products, including “How will we afford this?” said Dr. Leo. It is essential for plans to understand their populations to evaluate how hemophilia is being managed, he added.
Management challenges, meanwhile, include fragmentation of care and lack of uniformity, limited transparency, robust and complex product selection, lack of individualized treatment, potential stockpiling and product waste, pharmacy and medical benefit utilization, and navigating the need for reinsurance programs for high-cost members.
Among stakeholders, payers have little insight into clinical data outside of factor product cost, and providers may have limited insight into product utilization, dispensed amounts, and total healthcare resource utilization. “We need to promote proactive communication between stakeholders to optimize patient care,” Dr. Leo said.
Pharmacokinetic (PK)-guided dosing and assay management may result in a better patient-tailored approach, he noted. PK-guided dosing can provide better and more accurate targeting of factor levels, better ability to adapt dosing to lifestyle, and a potential reduction in cost and units utilized without compromising efficacy. However, doing this is time-intensive for both patients and providers, and many facilities do not have the capability to conduct PK testing. Medical and Scientific Advisory Council guidelines recommend dispensing of factor products to be within plus or minus 10% of prescribed assays, and many specialty pharmacies will “guarantee” assay management within narrower ranges, but it is difficult for payers to measure and monitor.
Dr. Tesaro then discussed management strategies. First, utilization management ensures specific standards of care, improves transparency and data collection (e.g., bleed history, reason for treatment, product utilized), and improves care coordination. Pharmacy management should include standardized assay and inventory management, bleed history tracking, no auto-refills, standards of care for patient engagement and clinical contacts, and adherence monitoring and counseling. Product preferencing can also be used, but he noted that this concept is not intended for patients already on a certain therapy, but for those with “new starts.” Data collection and analysis is also very important to determine benchmarks and measure relevant outcomes.
Dr. Tesaro’s organization rolled out a hemophilia program in July 2017 that added a prior authorization to the medical benefit. This included PK testing for high-risk patients and dispensing pharmacies were required to manage assays to a standardized range and to report monthly drug inventory and bleed history. After six months, 50% of patients in the population had an average reduction in dose either through assay management or PK testing.
Presentation: Managing Patients with Hemophilia: A Payer’s Perspective. AMCP Annual Meeting 2018 Specialty Connect.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Hemophilia Care From the Payer Perspective

AMCP 2018

Hemophilia is a costly and complex disease, and while there has been “incredible growth” in treatment options—48 products are currently on the market—the increased ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe